79
60
Growth Score
-12 pts
Heat Score
-18 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
223360
Origami Therapeutics develops protein degrader therapeutics.
- Leslie Schulze: Co-founder and CFO
- Beth Hoffman: Co-Founder and CEO
About the Company
Origami Therapeutics is developing medicines that target and degrade disease-related proteins as a means of treating disease. They're a preclinical biopharmaceutical company determined to find innovative treatments for neurological disorders, starting with Huntington's disease. Their new protein degraders digest and eliminate
disease-causing proteins by utilizing the body's natural protein disposal system. Neurodegenerative disorders such as Alzheimer's, Parkinson's, amyotrophic lateral sclerosis, and frontotemporal dementia are the target of its core programs.
